West Pharmaceutical Services Inc. (WST)
NYSE: WSTHealth CareMedical/Dental InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
WST stock chart
Technical analysisKey statistics
All statistics- Market cap
- $25.79B
- P/E (TTM)
- 46.92
- Forward P/E
- 36.72
- EPS (TTM)
- $7.81
- Dividend yield
- 0.24% ($0.87)
- Ex-dividend date
- Jul 29, 2026
- 52-week range
- 223.83 – 386.00
- Day range
- 365.35 – 374.79
- Volume / Avg
- 437.98K / 629.98K
- Beta
- —
- Shares outstanding
- 70.38M
- Next earnings
- Oct 22, 2026
52-week range
WST stock today
West Pharmaceutical Services (WST) closed at $366.48 on Oct 7, down 1.65% (-$6.16), versus the S&P 500's 0.22% decline. At this level, WST sits near the top of its 52-week range of $223.83 to $386.00: 5.1% below the high, set on Jul 23, 2026 and 63.7% above the low. WST is up 33.2% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 37.8%.
At 46.9x trailing earnings, West Pharmaceutical Services trades above the peer-group median of 23.2x. Its forward P/E of 36.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 22; analysts expect EPS of $2.18. West Pharmaceutical Services pays an annual dividend of $0.87 per share, a 0.24% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About West Pharmaceutical Services
Company profileWest Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Michel Lagarde
- Headquarters
- Exton, PA
- Employees
- 10,800
- Website
- westpharma.com
Financial highlights
Full financialsIn fiscal 2025, West Pharmaceutical Services generated $3.07 billion in revenue, up 6.3% from fiscal 2024. Net income was $493.7 million (+0.2% year over year), for a net margin of 16.1% versus a median of 20.1% in the prior 5 years. Gross margin was 35.9% (up from 34.5%) and operating margin 19.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Growth | +6.25% | -1.92% | +2.18% | +1.95% | +31.89% |
| Net income | $493.70M | $492.70M | $593.40M | $585.90M | $661.80M |
| EPS (diluted) | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 |
Analyst forecast
ForecastConsensus (17 analysts)
strong_buy
Avg. price target
$411.00+12.15%
- Strong buy 4
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 22, 2026
- EPS estimate
- $2.18
- Last reported (Q2 2026)
- Jul 23, 2026
- EPS actual vs est.
- $2.15 vs —
Dividends
Dividend history- Annual dividend
- $0.87
- Dividend yield
- 0.24%
- Last payment
- $0.22
- Ex-dividend date
- Jul 29, 2026
WST news
All WST news- BDX Expands U.S. Manufacturing With $19B Healthcare InvestmentNasdaqBDX, WST, OPK, GMED
- Veeva's DQS Scales Data Automation Across 1,000+ Clinical StudiesNasdaqVEEV, WST, GMED, VCYT
- Reasons to Retain Cardinal Health Stock in Your Portfolio for NowNasdaqCAH, MMSI, WST, GMED
- Veeva's OpenData to Help Servier Build a Global AI Data FoundationNasdaqVEEV, WST, GMED, VCYT
- Inspire Medical Gains New CPT Codes for Hypoglossal Nerve StimulationNasdaqINSP, ISRG, WST, GMED
- Here's Why You Should Retain BDX Stock in Your Portfolio for NowNasdaqBDX, WST, GMED, VCYT
- Veeva Unveils AI Study Builder Agent to Speed Clinical Trial SetupNasdaqVEEV, WST, GMED, VCYT
- Veeva Unveils Falcon Router to Streamline Biopharma Case RoutingNasdaqVEEV, WST, GMED, VCYT
West Pharmaceutical Services peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RMDResMed Inc. | 225.98 | +2.40% | $31.78B | vs WST |
| DXCMDexCom Inc. | 84.30 | +1.09% | $31.81B | vs WST |
| SOLVSolventum Corporation | 85.88 | -1.33% | $14.62B | vs WST |
| PENPenumbra Inc. | 316.35 | -0.22% | $12.46B | vs WST |
| BAXBaxter International Inc. | 23.97 | -1.60% | $12.39B | vs WST |
| GKOSGlaukos Corporation | 172.18 | +6.55% | $10.16B | vs WST |
| GMEDGlobus Medical Inc. Class A | 73.75 | -3.51% | $9.90B | vs WST |
| PODDInsulet Corporation | 134.36 | -0.27% | $9.32B | vs WST |
Indexes, lists and sector
Index membership
Appears in lists
West Pharmaceutical Services stock FAQ
What is West Pharmaceutical Services's stock price today?
WST last traded at $366.48 as of Oct 7, 4:00 PM EDT, down 1.65% on the day. Prices are delayed at least 15 minutes.
Does West Pharmaceutical Services pay a dividend?
Yes. West Pharmaceutical Services pays $0.87 per share annually, a 0.24% yield. The most recent dividend of $0.22 had an ex-dividend date of Jul 29, 2026.
When is West Pharmaceutical Services's next earnings date?
West Pharmaceutical Services is expected to report earnings on Thursday, October 22, 2026. Analysts expect EPS of $2.18.
What is WST's P/E ratio?
WST trades at a trailing P/E ratio of 46.92 and a forward P/E of 36.72, compared with a median of 23.2 for its closest peers.
Is West Pharmaceutical Services in the S&P 500?
Yes. West Pharmaceutical Services (WST) is a constituent of the S&P 500 index.
Who is West Pharmaceutical Services's CEO?
Mr. Michel Lagarde is the chief executive officer of West Pharmaceutical Services Inc., which has about 10,800 employees.
Has WST ever split its stock?
Yes. The most recent WST stock split was a 2-for-1 split on Sep 27, 2013, one of 4 splits on record.